Si et al., 2024 - Google Patents

Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications

Si et al., 2024

View HTML @Full View
Document ID
12454987110273485800
Author
Si C
Gao J
Ma X
Publication year
Publication venue
Molecular cancer

External Links

Snippet

Natural killer (NK) cells are important immune cells in the organism and are the third major type of lymphocytes besides T cells and B cells, which play an important function in cancer therapy. In addition to retaining the tumor cell killing function of natural killer cells, natural …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Si et al. Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications
Xia et al. Engineering macrophages for cancer immunotherapy and drug delivery
Hu et al. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy
Zhang et al. Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
Ci et al. Delivery strategies in treatments of leukemia
Rakshit et al. Extracellular vesicles for drug delivery and theranostics in vivo
Guo et al. Magnetic metal–Organic Framework-based nanoplatform with platelet membrane coating as a synergistic programmed cell death protein 1 inhibitor against Hepatocellular Carcinoma
Chen et al. Orchestration of biomimetic membrane coating and nanotherapeutics in personalized anticancer therapy
Ling et al. Mn2+/CpG oligodeoxynucleotides codecorated black phosphorus nanosheet platform for enhanced antitumor potency in multimodal therapy
Thomas et al. Exosomes: biological pharmaceutical nanovectors for theranostics
Xu et al. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy
Lu et al. Cancer cell membrane‐based materials for biomedical applications
Jin et al. Different origin-derived exosomes and their clinical advantages in cancer therapy
Lahouty et al. Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment
AU2018227801A1 (en) PM21 particles to improve bone marrow homing of NK cells
Zeng et al. Advancements in cell membrane-derived biomimetic nanotherapeutics for breast cancer
Graner Roles of extracellular vesicles in high-grade gliomas: tiny particles with outsized influence
Zhang et al. The current role of dendritic cells in the progression and treatment of colorectal cancer
Malla et al. ROS-responsive nanomedicine: towards targeting the breast tumor microenvironment
Zhang et al. Research progress of cell membrane biomimetic nanoparticles for circulating tumor cells
Patras et al. Intercellular crosstalk via extracellular vesicles in tumor milieu as emerging therapies for cancer progression
Xia et al. Prospect of extracellular vesicles in tumor immunotherapy
Tang et al. Engineered extracellular vesicles: an emerging nanomedicine therapeutic platform
Li et al. Zinc-loaded black phosphorus multifunctional nanodelivery system combined with photothermal therapy have the potential to treat prostate cancer patients infected with COVID-19
Alfawaz Altamimi et al. Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer